This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Brooks Automation Management Presents At Morgan Stanley Technology, Media & Telecom Conference (Transcript)

Brooks Automation (BRKS)

Morgan Stanley Technology, Media & Telecom Conference

Feb 29, 2012 04:00 PM ET

Executives

Martin Headley - CFO

Presentation

Unidentified Analyst

Good afternoon everyone and thank you for coming. My name is Ms. Valerie and I'm member of the semiconductor and capital equipment equity research team here at Morgan Stanley. It's my pleasure to welcome Martin Headley, CFO of Brooks Automation. Martin is going to kick us off with some high level comments, opportunities for 2012 and then we'll jump into some Q&A.

Martin Headley

Thank you very much. I think it's best to frame what's top of mind with Brooks by maybe five significant priorities that we have at the moment. Firstly its integrating our new and very exciting Brooks Life Science Systems business into Brooks. This is a business that we entered with the acquisitions of RTF Life Sciences and Nexus Bio Systems during the course of 2011 and followed up with a very exciting product line acquisition of an automated Cytometer called Celigo in December of 2011 and this is a business that we see having a growth potential of over 20% per annum driven by personalized medicine initiatives that are really expanding the amount of biological samples that are being stored on this earth to facilitate those initiatives and we see the amount of samples being stored growing at somewhere between 25% and 30% per year and really being the fuel behind the driver for a fully effective sample management solution that will enable a better yield of the samples available from storage.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,550.69 -47.51 -0.27%
S&P 500 2,093.32 -4.72 -0.22%
NASDAQ 5,105.5460 -9.8360 -0.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs